@article{9bce99d35a3842cf8536da03f33c1f4d,
title = "Retreatment of Recurrent or Second Primary Head and Neck Cancer After Prior Radiation: Executive Summary of the American Radium Society Appropriate Use Criteria",
abstract = "Retreatment of recurrent or second primary head and neck cancers occurring in a previously irradiated field is complex. Few guidelines exist to support practice. We performed an updated literature search of peer-reviewed journals in a systematic fashion. Search terms, key questions, and associated clinical case variants were formed by panel consensus. The literature search informed the committee during a blinded vote on the appropriateness of treatment options via the modified Delphi method. The final number of citations retained for review was 274. These informed 5 key questions, which focused on patient selection, adjuvant reirradiation, definitive reirradiation, stereotactic body radiation, and reirradiation to treat nonsquamous cancer. Results of the consensus voting are presented along with discussion of the most current evidence. This provides updated evidence-based recommendations and guidelines for the retreatment of recurrent or second primary cancer of the head and neck.",
author = "Ward, {Matthew C.} and Koyfman, {Shlomo A.} and Bakst, {Richard L.} and Margalit, {Danielle N.} and Beadle, {Beth M.} and Beitler, {Jonathan J.} and Chang, {Steven Shih Wei} and Cooper, {Jay S.} and Galloway, {Thomas J.} and Ridge, {John A.} and Robbins, {Jared R.} and Sacco, {Assuntina G.} and Tsai, {C. Jillian} and Yom, {Sue S.} and Farzan Siddiqui",
note = "Funding Information: Disclosures: All panelists were required to declare all potential conflicts of interest dating back 36 months before initiating work on this document. These complete disclosure forms are permanently retained by the American Radium Society. The American Radium Society Appropriate Use Criteria Steering Committee reviewed these disclosures with the chair and cochair of this document's committee and approved participation of the panelists before starting development of this work. Disclosures potentially relevant to the content of this guideline are as follows: M.C.W. reports research support paid to institution from Varian Medical Systems and Naveris, Inc, and is on the advisory board for Bayer, Inc. A.G.S. reports research support from Merck, and is on the advisory board of and receives consultant fees from Bicara. S.S.Y. reports grants paid to institution from Genentech, Merck, Bristol-Myers Squibb, BioMimetix; royalties from Springer and UpToDate; and honoraria from the American Society for Radiation Oncology. F.S. reports an honorarium for lectures from Varian Medical Systems, is an American College of Radiology site surveyor, and is on the Medical Advisory Board for Varian Noona. T.G. reports royalties from UpToDate and honoraria from Varian Medical Systems. S.K. reports research funding from Merck, BMC, and Castle Biosciences, and honoraria from UpToDate, and is on the advisory board of Merck, Regeneron, and Castle Biosciences. D.M. is a senior editor for International Journal of Radiation Oncology • Biology • Physics. Funding Information: Disclosures: All panelists were required to declare all potential conflicts of interest dating back 36 months before initiating work on this document. These complete disclosure forms are permanently retained by the American Radium Society. The American Radium Society Appropriate Use Criteria Steering Committee reviewed these disclosures with the chair and cochair of this document's committee and approved participation of the panelists before starting development of this work. Disclosures potentially relevant to the content of this guideline are as follows: M.C.W. reports research support paid to institution from Varian Medical Systems and Naveris, Inc, and is on the advisory board for Bayer, Inc. A.G.S. reports research support from Merck, and is on the advisory board of and receives consultant fees from Bicara. S.S.Y. reports grants paid to institution from Genentech, Merck, Bristol-Myers Squibb, BioMimetix; royalties from Springer and UpToDate; and honoraria from the American Society for Radiation Oncology. F.S. reports an honorarium for lectures from Varian Medical Systems, is an American College of Radiology site surveyor, and is on the Medical Advisory Board for Varian Noona. T.G. reports royalties from UpToDate and honoraria from Varian Medical Systems. S.K. reports research funding from Merck, BMC, and Castle Biosciences, and honoraria from UpToDate, and is on the advisory board of Merck, Regeneron, and Castle Biosciences. D.M. is a senior editor for International Journal of Radiation Oncology • Biology • Physics. Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",
year = "2022",
month = jul,
day = "15",
doi = "10.1016/j.ijrobp.2022.03.034",
language = "English",
volume = "113",
pages = "759--786",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",
}